n N = 67 | CTC positive (%) | p-value | AR-positive CTC (%) | p-value | |
---|---|---|---|---|---|
Total | 67 | 37 (55) | 16 (43) | ||
Menopausal status | 0.40 | 0.68 | |||
premenopausal | 12 | 7 (58) | 4 (57) | ||
postmenopausal | 53 | 28 (53) | 11 (39) | ||
unknown | 2 | 2 (100) | 1 (50) | ||
Line of treatment | 0.75 | 0.30 | |||
1st | 26 | 15 (58) | 8 (53) | ||
≥ 2nd | 41 | 22 (54) | 8 (36) | ||
IHC tumour type | 0.94 | 0.56 | |||
TNBC | 10 | 6 (60) | 2 (33) | ||
HR+/HER2- | 55 | 30 (54) | 14 (47) | ||
HR+/HER2 + a | 2 | 1 (50) | 0 | ||
Site of metastasis | 0.65 | 0.44 | |||
bone only | 14 | 8 (57) | 4 (50) | ||
other site | 52 | 28 (54) | 11 (39) | ||
unknown | 1 | 1 (100) | 1 (100) |